<h2 data-section-id="1cgurzj" data-start="0" data-end="42"><strong>Agitation in Alzheimer&rsquo;s Disease Market</strong></h2>
<p data-start="44" data-end="662">The <a href="https://www.delveinsight.com/report-store/agitation-in-alzheimer-disease"><strong>Agitation in Alzheimer&rsquo;s Disease market</strong></a> is witnessing notable expansion across the 7MM, driven by the increasing prevalence of Alzheimer&rsquo;s disease and the growing recognition of neuropsychiatric symptoms associated with dementia. In 2025, the market size reached nearly USD 600 million across the 7MM and is projected to grow at a CAGR of 14.9% during 2026-2036. The US accounted for the largest market share with approximately 83%, followed by Japan (9%) and the EU4 and the UK (8%). The approval of <span class="whitespace-normal">REXULTI</span> marked a major advancement toward indication-specific treatment approaches.</p>
<ul data-start="664" data-end="944">
<li data-section-id="1tlbhea" data-start="664" data-end="737">Rising global Alzheimer&rsquo;s disease burden is boosting treatment demand</li>
<li data-section-id="89e2fl" data-start="738" data-end="797">Growing focus on targeted and mechanism-based therapies</li>
<li data-section-id="15qenhu" data-start="798" data-end="869">Increasing healthcare expenditure and clinical research investments</li>
<li data-section-id="165ujz0" data-start="870" data-end="944">COBENFY is expected to generate the highest revenue by 2036 in the 7MM</li>
</ul>
<h2 data-section-id="1xv7ubk" data-start="951" data-end="999"><strong>Agitation in Alzheimer&rsquo;s Disease Epidemiology</strong></h2>
<p data-start="1001" data-end="1697"><a href="https://www.delveinsight.com/report-store/agitation-in-alzheimers-disease-epidemiology-forecast"><strong>Agitation in Alzheimer&rsquo;s Disease</strong></a> represents a significant neuropsychiatric burden affecting millions of patients globally. In 2025, the total diagnosed prevalent cases of Alzheimer&rsquo;s disease across the 7MM were estimated at nearly 11 million. Among these, approximately 5 million diagnosed cases of agitation associated with Alzheimer&rsquo;s disease were reported in the US alone, highlighting the substantial unmet clinical need. Epidemiological segmentation further evaluates diagnosed prevalent cases by age, gender, and treated population. Females accounted for the majority of diagnosed cases in the EU4 and the UK due to longer life expectancy and higher dementia prevalence among elderly women.</p>
<h3 data-section-id="1jv18un" data-start="1699" data-end="1728"><strong>Key Epidemiology Insights</strong></h3>
<ul data-start="1729" data-end="1906">
<li data-section-id="1qvcdfu" data-start="1729" data-end="1777">Total diagnosed cases in the 7MM: 11 million</li>
<li data-section-id="168hmpl" data-start="1778" data-end="1828">US diagnosed agitation cases: nearly 5 million</li>
<li data-section-id="1i87sf2" data-start="1829" data-end="1868">Female cases in EU4 and the UK: 70%</li>
<li data-section-id="g8zt4p" data-start="1869" data-end="1906">Male cases in EU4 and the UK: 30%</li>
</ul>
<h3 data-section-id="1k0ugar" data-start="1908" data-end="1946"><strong>Japan Age-specific Diagnosed Cases</strong></h3>
<ul data-start="1947" data-end="2025">
<li data-section-id="13zh8zr" data-start="1947" data-end="1964">&lt;65 years: 3%</li>
<li data-section-id="1ca07x" data-start="1965" data-end="1985">65-74 years: 14%</li>
<li data-section-id="1tlgya" data-start="1986" data-end="2006">75-84 years: 51%</li>
<li data-section-id="1cuh0g2" data-start="2007" data-end="2025">&ge;85 years: 32%</li>
</ul>
<h2 data-section-id="6z8015" data-start="2032" data-end="2076"><strong>Agitation in Alzheimer&rsquo;s Disease Pipeline</strong></h2>
<p data-start="2078" data-end="2706">The pipeline for Agitation in Alzheimer&rsquo;s Disease is evolving rapidly with several companies developing mechanism-driven therapies to improve efficacy and safety outcomes. Current research focuses on serotonergic, glutamatergic, cholinergic, and NMDA-modulating pathways to address agitation symptoms more precisely. Despite recent progress, major unmet needs remain, including limited standardized assessment tools, safety concerns with antipsychotics, and challenges in implementing nonpharmacological interventions at scale. Several emerging therapies are expected to reshape the treatment landscape over the forecast period.</p>
<h3 data-section-id="1dciitl" data-start="2708" data-end="2726"><strong>Emerging Drugs</strong></h3>
<ul data-start="2727" data-end="3044">
<li data-section-id="18lq6rb" data-start="2727" data-end="2794"><span class="whitespace-normal">Masupirdine</span> - 5-HT6 antagonist (Oral)</li>
<li data-section-id="7igz57" data-start="2795" data-end="2870"><span class="whitespace-normal">AUVELITY</span> - NMDA receptor antagonist (Oral)</li>
<li data-section-id="szi3o9" data-start="2871" data-end="2956"><span class="whitespace-normal">COBENFY</span> - Muscarinic M1/M4 receptor agonists (Oral)</li>
<li data-section-id="1n0kk6o" data-start="2957" data-end="3044"><span class="whitespace-normal">EXV-801</span> - Modulates NMDA and sigma-1 receptors (Oral)</li>
</ul>
<h3 data-section-id="1nxroaa" data-start="3046" data-end="3072"><strong>Key Pipeline Companies</strong></h3>
<ul data-start="3073" data-end="3280" data-is-last-node="" data-is-only-node="">
<li data-section-id="hjs5dh" data-start="3073" data-end="3114"><span class="whitespace-normal">Bristol Myers Squibb</span></li>
<li data-section-id="pzvh1x" data-start="3115" data-end="3156"><span class="whitespace-normal">Suven Life Sciences</span></li>
<li data-section-id="1l5awad" data-start="3157" data-end="3198"><span class="whitespace-normal">Axsome Therapeutics</span></li>
<li data-section-id="1upsd79" data-start="3199" data-end="3240"><span class="whitespace-normal">Exciva GmbH</span></li>
<li data-section-id="4w1vzp" data-start="3241" data-end="3280" data-is-last-node=""><span class="whitespace-normal">IGC Pharma</span></li>
</ul>

Agitation in Alzheimer’s Disease Market

Agitation in Alzheimer’s Disease Market Infographic

Agitation in Alzheimer’s Disease Market Thumbnail

Agitation in Alzheimer’s Disease Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape